{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:50:57Z","timestamp":1790117457261,"version":"4.0.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U19 HL129903"],"award-info":[{"award-number":["U19 HL129903"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32 AI007632"],"award-info":[{"award-number":["T32 AI007632"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["F32 AI136750"],"award-info":[{"award-number":["F32 AI136750"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19 AI117950"],"award-info":[{"award-number":["U19 AI117950"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI126620"],"award-info":[{"award-number":["UM1 AI126620"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1038\/s41591-020-1039-5","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T12:04:06Z","timestamp":1598875446000},"page":"1776-1787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo"],"prefix":"10.1038","volume":"26","author":[{"given":"Colby R.","family":"Maldini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Claiborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Okawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick L.","family":"Dopkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochuan","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Power","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6191-1970","authenticated-orcid":false,"given":"Radiana T.","family":"Trifonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Krupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3522-4226","authenticated-orcid":false,"given":"Meredith","family":"Phelps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir D.","family":"Vrbanac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serah","family":"Tanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Bateson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Hoxie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian L.","family":"Boutwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1057-576X","authenticated-orcid":false,"given":"James L.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6609-1318","authenticated-orcid":false,"given":"Todd M.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"1039_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1039_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a007054","volume":"2","author":"B Walker","year":"2012","unstructured":"Walker, B. & McMichael, A. The T-cell response to HIV. Cold Spring Harb. Perspect. Med. 2, 1\u201319 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1039_CR3","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross, G., Waks, T. & Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86, 10024\u201310028 (1989).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1039_CR4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJ van der Stegen","year":"2015","unstructured":"van der Stegen, S. J., Hamieh, M. & Sadelain, M. The pharmacology of second-generation chimeric antigen receptors. Nat. Rev. Drug Disco. 14, 499\u2013509 (2015).","journal-title":"Nat. Rev. Drug Disco."},{"key":"1039_CR5","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1039_CR6","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).","journal-title":"Sci. Transl. Med."},{"key":"1039_CR7","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","volume":"13","author":"RJ Brentjens","year":"2007","unstructured":"Brentjens, R. J. et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13, 5426\u20135435 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1039_CR8","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","volume":"71","author":"DG Song","year":"2011","unstructured":"Song, D. G. et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 71, 4617\u20134627 (2011).","journal-title":"Cancer Res."},{"key":"1039_CR9","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","volume":"106","author":"C Carpenito","year":"2009","unstructured":"Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106, 3360\u20133365 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1039_CR10","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453\u20131464 (2009).","journal-title":"Mol. Ther."},{"key":"1039_CR11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ymthe.2018.01.022","volume":"26","author":"Z Cheng","year":"2018","unstructured":"Cheng, Z. et al. In vivo expansion and antitumor activity of coinfused CD28- and 4-1BB-engineered CAR-T cells in patients with B cell leukemia. Mol. Ther. 26, 976\u2013985 (2018).","journal-title":"Mol. Ther."},{"key":"1039_CR12","doi-asserted-by":"publisher","first-page":"e1433518","DOI":"10.1080\/2162402X.2018.1433518","volume":"7","author":"C Quintarelli","year":"2018","unstructured":"Quintarelli, C. et al. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology 7, e1433518 (2018).","journal-title":"Oncoimmunology"},{"key":"1039_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 380\u2013390 (2016).","journal-title":"Immunity"},{"key":"1039_CR14","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1039_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1039_CR16","doi-asserted-by":"publisher","first-page":"eaat6753","DOI":"10.1126\/scisignal.aat6753","volume":"11","author":"AI Salter","year":"2018","unstructured":"Salter, A. I. et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci. Signal. 11, eaat6753 (2018).","journal-title":"Sci. Signal."},{"key":"1039_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1039_CR18","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/mto.2016.14","volume":"3","author":"D Abate-Daga","year":"2016","unstructured":"Abate-Daga, D. & Davila, M. L. CAR models: next-generation CAR modifications for enhanced T-cell function. Mol. Ther. Oncolytics 3, 16014 (2016).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1039_CR19","doi-asserted-by":"publisher","first-page":"e1049","DOI":"10.1002\/cti2.1049","volume":"8","author":"R Weinkove","year":"2019","unstructured":"Weinkove, R., George, P., Dasyam, N. & McLellan, A. D. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin. Transl. Immunol. 8, e1049 (2019).","journal-title":"Clin. Transl. Immunol."},{"key":"1039_CR20","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1006\/mthe.2002.0611","volume":"5","author":"SG Deeks","year":"2002","unstructured":"Deeks, S. G. et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol. Ther. 5, 788\u2013797 (2002).","journal-title":"Mol. Ther."},{"key":"1039_CR21","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2217\/imt.12.91","volume":"4","author":"C Colovos","year":"2012","unstructured":"Colovos, C., Villena-Vargas, J. & Adusumilli, P. S. Safety and stability of retrovirally transduced chimeric antigen receptor T cells. Immunotherapy 4, 899\u2013902 (2012).","journal-title":"Immunotherapy"},{"key":"1039_CR22","doi-asserted-by":"publisher","first-page":"132ra153","DOI":"10.1126\/scitranslmed.3003761","volume":"4","author":"J Scholler","year":"2012","unstructured":"Scholler, J. et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132ra153 (2012).","journal-title":"Sci. Transl. Med."},{"key":"1039_CR23","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.3389\/fimmu.2019.02310","volume":"10","author":"GB Kim","year":"2019","unstructured":"Kim, G. B., Hege, K. & Riley, J. L. CAR talk: how cancer-specific CAR T cells can instruct how to build CAR T cells to cure HIV. Front. Immunol. 10, 2310 (2019).","journal-title":"Front. Immunol."},{"key":"1039_CR24","doi-asserted-by":"publisher","first-page":"6999","DOI":"10.1128\/JVI.00805-16","volume":"90","author":"A Ali","year":"2016","unstructured":"Ali, A. et al. HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. J. Virol. 90, 6999\u20137006 (2016).","journal-title":"J. Virol."},{"key":"1039_CR25","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ymthe.2016.12.023","volume":"25","author":"M Hale","year":"2017","unstructured":"Hale, M. et al. Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells. Mol. Ther. 25, 570\u2013579 (2017).","journal-title":"Mol. Ther."},{"key":"1039_CR26","doi-asserted-by":"publisher","first-page":"e1006613","DOI":"10.1371\/journal.ppat.1006613","volume":"13","author":"RS Leibman","year":"2017","unstructured":"Leibman, R. S. et al. Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathog. 13, e1006613 (2017).","journal-title":"PLoS Pathog."},{"key":"1039_CR27","doi-asserted-by":"publisher","first-page":"e1006753","DOI":"10.1371\/journal.ppat.1006753","volume":"13","author":"A Zhen","year":"2017","unstructured":"Zhen, A. et al. Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV\/AIDS. PLoS Pathog. 13, e1006753 (2017).","journal-title":"PLoS Pathog."},{"key":"1039_CR28","doi-asserted-by":"publisher","first-page":"eaav5685","DOI":"10.1126\/scitranslmed.aav5685","volume":"11","author":"K Anthony-Gonda","year":"2019","unstructured":"Anthony-Gonda, K. et al. Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. Sci. Transl. Med. 11, eaav5685 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1039_CR29","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/j.cell.2019.10.002","volume":"179","author":"E Herzig","year":"2019","unstructured":"Herzig, E. et al. Attacking latent HIV with convertibleCAR-T cells, a highly adaptable killing platform. Cell 179, e810 (2019).","journal-title":"Cell"},{"key":"1039_CR30","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1084\/jem.20062411","volume":"204","author":"Z Sun","year":"2007","unstructured":"Sun, Z. et al. Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J. Exp. Med. 204, 705\u2013714 (2007).","journal-title":"J. Exp. Med."},{"key":"1039_CR31","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1371\/journal.pmed.0050016","volume":"5","author":"PW Denton","year":"2008","unstructured":"Denton, P. W. et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5, e16 (2008).","journal-title":"PLoS Med."},{"key":"1039_CR32","doi-asserted-by":"publisher","first-page":"7305","DOI":"10.1128\/JVI.02207-08","volume":"83","author":"DM Brainard","year":"2009","unstructured":"Brainard, D. M. et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J. Virol. 83, 7305\u20137321 (2009).","journal-title":"J. Virol."},{"key":"1039_CR33","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1172\/JCI89488","volume":"127","author":"A Zhen","year":"2017","unstructured":"Zhen, A. et al. Targeting type I interferon-mediated activation restores immune function in chronic HIV infection. J. Clin. Invest. 127, 260\u2013268 (2017).","journal-title":"J. Clin. Invest."},{"key":"1039_CR34","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cell.2016.06.039","volume":"166","author":"EA Boritz","year":"2016","unstructured":"Boritz, E. A. et al. Multiple origins of virus persistence during natural control of HIV infection. Cell 166, 1004\u20131015 (2016).","journal-title":"Cell"},{"key":"1039_CR35","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/nm.4411","volume":"23","author":"JD Estes","year":"2017","unstructured":"Estes, J. D. et al. Defining total-body AIDS-virus burden with implications for curative strategies. Nat. Med. 23, 1271\u20131276 (2017).","journal-title":"Nat. Med."},{"key":"1039_CR36","doi-asserted-by":"publisher","first-page":"e1008161","DOI":"10.1371\/journal.ppat.1008161","volume":"15","author":"JD Ventura","year":"2019","unstructured":"Ventura, J. D. et al. Longitudinal bioluminescent imaging of HIV-1 infection during antiretroviral therapy and treatment interruption in humanized mice. PLoS Pathog. 15, e1008161 (2019).","journal-title":"PLoS Pathog."},{"key":"1039_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","volume":"571","author":"F Alfei","year":"2019","unstructured":"Alfei, F. et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571, 265\u2013269 (2019).","journal-title":"Nature"},{"key":"1039_CR38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211\u2013218 (2019).","journal-title":"Nature"},{"key":"1039_CR39","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","volume":"571","author":"AC Scott","year":"2019","unstructured":"Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270\u2013274 (2019).","journal-title":"Nature"},{"key":"1039_CR40","doi-asserted-by":"publisher","first-page":"12410","DOI":"10.1073\/pnas.1905675116","volume":"116","author":"H Seo","year":"2019","unstructured":"Seo, H. et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc. Natl Acad. Sci. USA 116, 12410\u201312415 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1039_CR41","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/s41590-019-0403-4","volume":"20","author":"C Yao","year":"2019","unstructured":"Yao, C. et al. Single-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic infection. Nat. Immunol. 20, 890\u2013901 (2019).","journal-title":"Nat. Immunol."},{"key":"1039_CR42","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nm0402-379","volume":"8","author":"V Appay","year":"2002","unstructured":"Appay, V. et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8, 379\u2013385 (2002).","journal-title":"Nat. Med."},{"key":"1039_CR43","doi-asserted-by":"publisher","first-page":"e1004251","DOI":"10.1371\/journal.ppat.1004251","volume":"10","author":"M Buggert","year":"2014","unstructured":"Buggert, M. et al. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog. 10, e1004251 (2014).","journal-title":"PLoS Pathog."},{"key":"1039_CR44","doi-asserted-by":"publisher","first-page":"e1005983","DOI":"10.1371\/journal.ppat.1005983","volume":"12","author":"GJ Leslie","year":"2016","unstructured":"Leslie, G. J. et al. Potent and broad inhibition of HIV-1 by a peptide from the gp41 heptad repeat-2 domain conjugated to the CXCR4 amino terminus. PLoS Pathog. 12, e1005983 (2016).","journal-title":"PLoS Pathog."},{"key":"1039_CR45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415\u2013428 (2015).","journal-title":"Cancer Cell"},{"key":"1039_CR46","doi-asserted-by":"publisher","first-page":"e96976","DOI":"10.1172\/jci.insight.96976","volume":"3","author":"S Guedan","year":"2018","unstructured":"Guedan, S. et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 3, e96976 (2018).","journal-title":"JCI Insight"},{"key":"1039_CR47","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","volume":"12","author":"MA Pule","year":"2005","unstructured":"Pule, M. A. et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther. 12, 933\u2013941 (2005).","journal-title":"Mol. Ther."},{"key":"1039_CR48","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/onci.19855","volume":"1","author":"AA Hombach","year":"2012","unstructured":"Hombach, A. A., Heiders, J., Foppe, M., Chmielewski, M. & Abken, H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells. Oncoimmunology 1, 458\u2013466 (2012).","journal-title":"Oncoimmunology"},{"key":"1039_CR49","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-011110-130254","volume":"6","author":"S Moir","year":"2011","unstructured":"Moir, S., Chun, T. W. & Fauci, A. S. Pathogenic mechanisms of HIV disease. Annu. Rev. Pathol. 6, 223\u2013248 (2011).","journal-title":"Annu. Rev. Pathol."},{"key":"1039_CR50","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nbt1410","volume":"26","author":"EE Perez","year":"2008","unstructured":"Perez, E. E. et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 26, 808\u2013816 (2008).","journal-title":"Nat. Biotechnol."},{"key":"1039_CR51","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nbt.1663","volume":"28","author":"N Holt","year":"2010","unstructured":"Holt, N. et al. Human hematopoietic stem\/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 28, 839\u2013847 (2010).","journal-title":"Nat. Biotechnol."},{"key":"1039_CR52","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJMoa1300662","volume":"370","author":"P Tebas","year":"2014","unstructured":"Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901\u2013910 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1039_CR53","doi-asserted-by":"publisher","first-page":"e1006956","DOI":"10.1371\/journal.ppat.1006956","volume":"14","author":"CW Peterson","year":"2018","unstructured":"Peterson, C. W. et al. Differential impact of transplantation on peripheral and tissue-associated viral reservoirs: implications for HIV gene therapy. PLoS Pathog. 14, e1006956 (2018).","journal-title":"PLoS Pathog."},{"key":"1039_CR54","doi-asserted-by":"publisher","first-page":"E1480","DOI":"10.1073\/pnas.1421607112","volume":"112","author":"DT Claiborne","year":"2015","unstructured":"Claiborne, D. T. et al. Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression. Proc. Natl Acad. Sci. USA 112, E1480\u2013E1489 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1039_CR55","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1128\/JVI.02520-10","volume":"85","author":"JK Wright","year":"2011","unstructured":"Wright, J. K. et al. Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C. J. Virol. 85, 3996\u20134006 (2011).","journal-title":"J. Virol."},{"key":"1039_CR56","doi-asserted-by":"publisher","first-page":"e1003041","DOI":"10.1371\/journal.ppat.1003041","volume":"8","author":"JL Prince","year":"2012","unstructured":"Prince, J. L. et al. Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. PLoS Pathog. 8, e1003041 (2012).","journal-title":"PLoS Pathog."},{"key":"1039_CR57","doi-asserted-by":"publisher","first-page":"e1005154","DOI":"10.1371\/journal.ppat.1005154","volume":"11","author":"MJ Deymier","year":"2015","unstructured":"Deymier, M. J. et al. Heterosexual transmission of subtype C HIV-1 selects consensus-like variants without increased replicative capacity or interferon-\u0251 resistance. PLoS Pathog. 11, e1005154 (2015).","journal-title":"PLoS Pathog."},{"issue":"Suppl 2","key":"1039_CR58","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1093\/infdis\/jit448","volume":"208","author":"E Seung","year":"2013","unstructured":"Seung, E. & Tager, A. M. Humoral immunity in humanized mice: a work in progress. J. Infect. Dis. 208(Suppl 2), S155\u2013S159 (2013).","journal-title":"J. Infect. Dis."},{"key":"1039_CR59","doi-asserted-by":"publisher","first-page":"e108663","DOI":"10.1371\/journal.pone.0108663","volume":"9","author":"F Martinez-Torres","year":"2014","unstructured":"Martinez-Torres, F., Nochi, T., Wahl, A., Garcia, J. V. & Denton, P. W. Hypogammaglobulinemia in BLT humanized mice\u2014an animal model of primary antibody deficiency. PLoS ONE 9, e108663 (2014).","journal-title":"PLoS ONE"},{"key":"1039_CR60","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.coviro.2015.05.002","volume":"13","author":"ME Karpel","year":"2015","unstructured":"Karpel, M. E., Boutwell, C. L. & Allen, T. M. BLT humanized mice as a small animal model of HIV infection. Curr. Opin. Virol. 13, 75\u201380 (2015).","journal-title":"Curr. Opin. Virol."},{"key":"1039_CR61","doi-asserted-by":"publisher","first-page":"143ra198","DOI":"10.1126\/scitranslmed.3003984","volume":"4","author":"TE Dudek","year":"2012","unstructured":"Dudek, T. E. et al. Rapid evolution of HIV-1 to functional CD8+ T cell responses in humanized BLT mice. Sci. Transl. Med. 4, 143ra198 (2012).","journal-title":"Sci. Transl. Med."},{"key":"1039_CR62","doi-asserted-by":"publisher","first-page":"e00814","DOI":"10.1128\/JVI.00814-19","volume":"93","author":"DT Claiborne","year":"2019","unstructured":"Claiborne, D. T. et al. Immunization of BLT humanized mice redirects T cell responses to Gag and reduces acute HIV-1 viremia. J. Virol. 93, e00814\u2013e00819 (2019).","journal-title":"J. Virol."},{"key":"1039_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14630","volume":"8","author":"N Pardi","year":"2017","unstructured":"Pardi, N. et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat. Commun. 8, 14630 (2017).","journal-title":"Nat. Commun."},{"key":"1039_CR64","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1128\/JVI.01970-08","volume":"83","author":"CL Boutwell","year":"2009","unstructured":"Boutwell, C. L., Rowley, C. F. & Essex, M. Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. J. Virol. 83, 2460\u20132468 (2009).","journal-title":"J. Virol."},{"key":"1039_CR65","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/0092-8674(86)90619-7","volume":"47","author":"D Johnson","year":"1986","unstructured":"Johnson, D. et al. Expression and structure of the human NGF receptor. Cell 47, 545\u2013554 (1986).","journal-title":"Cell"},{"key":"1039_CR66","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255\u20131263 (2011).","journal-title":"Blood"},{"key":"1039_CR67","doi-asserted-by":"publisher","first-page":"23736","DOI":"10.1074\/jbc.M000776200","volume":"275","author":"A Brelot","year":"2000","unstructured":"Brelot, A., Heveker, N., Montes, M. & Alizon, M. Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. J. Biol. Chem. 275, 23736\u201323744 (2000).","journal-title":"J. Biol. Chem."},{"key":"1039_CR68","doi-asserted-by":"publisher","first-page":"11117","DOI":"10.1128\/JVI.01046-08","volume":"82","author":"MW Richardson","year":"2008","unstructured":"Richardson, M. W. et al. Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5\u0251. J. Virol. 82, 11117\u201311128 (2008).","journal-title":"J. Virol."},{"key":"1039_CR69","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41590-018-0085-3","volume":"19","author":"KL Clayton","year":"2018","unstructured":"Clayton, K. L. et al. Resistance of HIV-infected macrophages to CD8+ T lymphocyte-mediated killing drives activation of the immune system. Nat. Immunol. 19, 475\u2013486 (2018).","journal-title":"Nat. Immunol."},{"key":"1039_CR70","doi-asserted-by":"publisher","first-page":"8604","DOI":"10.1021\/ac202028g","volume":"83","author":"BJ Hindson","year":"2011","unstructured":"Hindson, B. J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 83, 8604\u20138610 (2011).","journal-title":"Anal. Chem."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1039-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1039-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1039-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:24:18Z","timestamp":1788495858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1039-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":70,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1039"],"URL":"https:\/\/doi.org\/10.1038\/s41591-020-1039-5","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"assertion":[{"value":"27 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.R.M. and J.L.R. have filed an institution-owned patent (20180265565: Method of Redirecting T Cells to Treat HIV Infection) describing the construction of these HIV-specific CARs specific to Figs. 1 and 2. This patent application has been published but has not yet been granted. C.R.M. and J.L.R. have also filed an institution-owned patent (Dual CAR Expressing T Cells Individually Linked to CD28 and 4-1BB) specific to Figs. 4\u20136. G.J.L., J.A.H. and J.L.R. have also filed an institution-owned patent (Non-Signaling HIV Fusion Inhibitors And Methods Of Use Thereof) specific to Figs. 5 and 6. J.L.R. cofounded a company called Tmunity Therapeutics that has the rights to license the technology described in this paper. J.L.R. holds an equity interest in Tmunity. C.R.M. and J.L.R. declare no other competing financial interests. No other authors declare any competing financial interests. No authors declare any nonfinancial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}